GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » GF Value

Vaso (VASO) GF Value : $0.12 (As of May. 17, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vaso GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-17), Vaso's share price is $0.231. Vaso's GF Value is $0.12. Therefore, Vaso's Price-to-GF-Value for today is 1.93.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Vaso is Significantly Overvalued.


Vaso  (OTCPK:VASO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Vaso's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=0.231/0.12
=1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaso GF Value Related Terms

Thank you for viewing the detailed overview of Vaso's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaso (VASO) Business Description

Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
Leon Dembo director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen director 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma director C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios director 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher officer: Chief Financial Officer C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz director 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton officer: Vice Pres Finance & Controller 152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle director C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman director 3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi director C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill officer: Senior Vice President 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey director 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh officer: Chief Financial Officer C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone director
Derek Enlander director 88C UNION AVENUE, CENTER MORICHES NY 11934